JP2009531451A - 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物 - Google Patents

低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物 Download PDF

Info

Publication number
JP2009531451A
JP2009531451A JP2009503167A JP2009503167A JP2009531451A JP 2009531451 A JP2009531451 A JP 2009531451A JP 2009503167 A JP2009503167 A JP 2009503167A JP 2009503167 A JP2009503167 A JP 2009503167A JP 2009531451 A JP2009531451 A JP 2009531451A
Authority
JP
Japan
Prior art keywords
dosage
nsaid
dose
pharmaceutical composition
diclofenac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531451A5 (enExample
Inventor
カーティス ライト
ダニエル ビー カー
フレッド エイチ マーメルスタイン
Original Assignee
ジャヴェリン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャヴェリン ファーマシューティカルズ インコーポレイテッド filed Critical ジャヴェリン ファーマシューティカルズ インコーポレイテッド
Publication of JP2009531451A publication Critical patent/JP2009531451A/ja
Publication of JP2009531451A5 publication Critical patent/JP2009531451A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009503167A 2006-03-28 2007-03-22 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物 Pending JP2009531451A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78648706P 2006-03-28 2006-03-28
PCT/US2007/064683 WO2007112274A2 (en) 2006-03-28 2007-03-22 Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin

Publications (2)

Publication Number Publication Date
JP2009531451A true JP2009531451A (ja) 2009-09-03
JP2009531451A5 JP2009531451A5 (enExample) 2011-09-29

Family

ID=38541809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503167A Pending JP2009531451A (ja) 2006-03-28 2007-03-22 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物

Country Status (12)

Country Link
US (1) US20070232567A1 (enExample)
EP (1) EP2003970A4 (enExample)
JP (1) JP2009531451A (enExample)
KR (1) KR20090010953A (enExample)
CN (1) CN101410012A (enExample)
AU (1) AU2007230718B2 (enExample)
BR (1) BRPI0709410A2 (enExample)
CA (1) CA2647533A1 (enExample)
IL (1) IL194184A0 (enExample)
MX (1) MX2008012496A (enExample)
WO (1) WO2007112274A2 (enExample)
ZA (1) ZA200808114B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520893A (ja) * 2011-07-20 2014-08-25 ホスピーラ インコーポレイテッド 疼痛を治療する方法
JP2016525105A (ja) * 2013-07-19 2016-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
JP2023168541A (ja) * 2017-05-10 2023-11-24 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する固体医薬組成物の使用
US12257350B2 (en) 2013-12-04 2025-03-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
KR20170123724A (ko) * 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2702494A1 (en) 2007-10-19 2009-04-23 The Regents Of The University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
GB201021267D0 (en) 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN103405782A (zh) * 2013-08-29 2013-11-27 江苏正大清江制药有限公司 一种含塞来昔布的包合物及其制备方法
WO2016191744A1 (en) 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
AU2018376176A1 (en) 2017-11-30 2020-07-02 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid composition of ketoprofen, salts and enantiomers thereof
WO2021048748A1 (en) 2019-09-09 2021-03-18 Ftf Pharma Private Limited Pharmaceutical formulations comprising diclofenac
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain
CN116421569B (zh) * 2023-06-15 2023-09-05 四川尚锐生物医药有限公司 一种注射用帕瑞昔布钠药物组合物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252144A (ja) * 1993-12-02 1995-10-03 South African Druggist Ltd 薬学組成物
WO2004089418A1 (en) * 2003-04-14 2004-10-21 Dsm Ip Assets B.V. A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005092387A1 (en) * 2004-03-10 2005-10-06 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
JP2006502185A (ja) * 2002-09-18 2006-01-19 ボーン ケア インターナショナル インコーポレイテッド 親油性の薬剤のための組成物
JP2009531450A (ja) * 2006-03-28 2009-09-03 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
US5702724A (en) * 1993-06-08 1997-12-30 Ciba-Geigy Corporation Process for the preparation of an oral solid dosage form containing diclofenac
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
IT1291362B1 (it) * 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7186260B2 (en) * 1999-04-29 2007-03-06 Hyson Morton I Medicated wrap
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
AU2001259816A1 (en) * 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
BR0113625A (pt) * 2000-09-08 2003-07-22 Pharmacia Italia Spa Exemestano como agente de quimioprevenção
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US20040137062A1 (en) * 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
CA2504283A1 (en) * 2002-10-31 2004-05-21 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
WO2004050123A2 (en) * 2002-11-27 2004-06-17 Pharmacia Corporation Concentrated liquid valdecoxib composition
WO2004067678A1 (ja) * 2003-01-27 2004-08-12 Mitsubishi Corporation 抗酸化組成物と外用組成物
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
CA2518791A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell-schedule dependent anticancer agents
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
JP4947977B2 (ja) * 2003-10-31 2012-06-06 わかもと製薬株式会社 可逆性熱ゲル化水性組成物
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
US8128954B2 (en) * 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
EP1804751A2 (en) * 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1954275A2 (en) * 2005-11-21 2008-08-13 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
MY161894A (en) * 2006-09-08 2017-05-15 Abbvie Bahamas Ltd Interleukin-13 binding proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252144A (ja) * 1993-12-02 1995-10-03 South African Druggist Ltd 薬学組成物
JP2006502185A (ja) * 2002-09-18 2006-01-19 ボーン ケア インターナショナル インコーポレイテッド 親油性の薬剤のための組成物
WO2004089418A1 (en) * 2003-04-14 2004-10-21 Dsm Ip Assets B.V. A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005092387A1 (en) * 2004-03-10 2005-10-06 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
JP2009531450A (ja) * 2006-03-28 2009-09-03 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012027127; Ｊ．Ｐｈａｒｍ．Ｐｈｒａｍａｃｏｌ． Ｖｏｌ．５２, 2000, ｐ．９４９-９５６ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520893A (ja) * 2011-07-20 2014-08-25 ホスピーラ インコーポレイテッド 疼痛を治療する方法
JP2017110022A (ja) * 2011-07-20 2017-06-22 ホスピーラ インコーポレイテッド 疼痛を治療する方法
JP2016525105A (ja) * 2013-07-19 2016-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
US12357696B2 (en) 2013-07-19 2025-07-15 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US12257350B2 (en) 2013-12-04 2025-03-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
JP2023168541A (ja) * 2017-05-10 2023-11-24 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する固体医薬組成物の使用
JP7611981B2 (ja) 2017-05-10 2025-01-10 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する固体医薬組成物の使用

Also Published As

Publication number Publication date
ZA200808114B (en) 2009-12-30
MX2008012496A (es) 2009-01-07
CN101410012A (zh) 2009-04-15
EP2003970A2 (en) 2008-12-24
WO2007112274A2 (en) 2007-10-04
US20070232567A1 (en) 2007-10-04
EP2003970A4 (en) 2012-07-11
BRPI0709410A2 (pt) 2011-07-12
AU2007230718A1 (en) 2007-10-04
AU2007230718B2 (en) 2012-05-10
IL194184A0 (en) 2009-08-03
CA2647533A1 (en) 2007-10-04
WO2007112274A3 (en) 2008-08-21
KR20090010953A (ko) 2009-01-30

Similar Documents

Publication Publication Date Title
JP2009531451A (ja) 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物
JP5823093B2 (ja) 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
JP6095707B2 (ja) 薬学的組成物
BR112013010829B1 (pt) Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
JP2006509788A (ja) バルデコキシブの濃縮液体組成物
AU2012209035B9 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2009089269A1 (en) Methods of treating pain while minimizing adverse effects on platelet function
HK1180247A (en) Formulations of low dose diclofenac and beta-cyclodextrin
JP2017538762A (ja) パラセタモールの注射用製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130121